Exorcizing the devil of factor VIII inhibitors.
作者信息
Moorehead Paul C
机构信息
Discipline of Pediatrics, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Canada.
出版信息
Blood Adv. 2025 Aug 12;9(15):3716-3717. doi: 10.1182/bloodadvances.2025016643.
Abstract
摘要
相似文献
1
Exorcizing the devil of factor VIII inhibitors.驱除VIII因子抑制剂这个恶魔。
Blood Adv. 2025 Aug 12;9(15):3716-3717. doi: 10.1182/bloodadvances.2025016643.
2
Isolation of an infectious mammalian chu-like virus from tumor cells of the endangered Tasmanian devil (Sarcophilus harrisii).从濒危袋獾（袋獾属）的肿瘤细胞中分离出一种传染性哺乳动物类楚病毒。
Curr Biol. 2025 Jul 7;35(13):3278-3285.e5. doi: 10.1016/j.cub.2025.05.070. Epub 2025 Jun 26.
4
International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors.国际血液学标准化委员会关于因子 VIII 和 FIX 型 I 抑制剂的实验室测量建议。
Int J Lab Hematol. 2023 Aug;45(4):413-424. doi: 10.1111/ijlh.14109. Epub 2023 Jun 7.
5
Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.依非欧司他预防严重甲型血友病儿童出血
N Engl J Med. 2024 Jul 18;391(3):235-246. doi: 10.1056/NEJMoa2312611.
6
Efficacy, safety and satisfaction of using emicizumab in hemophilia A patients without factor VIII inhibitors: A systematic review.在无凝血因子VIII抑制剂的A型血友病患者中使用依美珠单抗的疗效、安全性及满意度：一项系统评价
Hematol Transfus Cell Ther. 2025 Jun 11;47(3):103849. doi: 10.1016/j.htct.2025.103849.
7
Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.曾接受治疗的血友病 A 患者的抑制剂发展：系统评价、荟萃分析和荟萃回归。
J Thromb Haemost. 2013 Sep;11(9):1655-62. doi: 10.1111/jth.12335.
8
Systematic review of the presentation of coagulation factor VIII inhibitors in rheumatic diseases: A potential cause of life-threatening hemorrhage.风湿性疾病中凝血因子 VIII 抑制剂表现的系统评价：危及生命出血的潜在原因
Semin Arthritis Rheum. 2015 Jun;44(6):695-709. doi: 10.1016/j.semarthrit.2014.11.008. Epub 2014 Dec 4.
9
Efanesoctocog Alfa versus Standard and Extended Half-Life Factor VIII Prophylaxis in Adolescent and Adult Patients with Haemophilia A without Inhibitors.依费奈索托考格阿尔法与标准及延长半衰期因子VIII预防治疗对无抑制物的青少年和成年甲型血友病患者的疗效比较
Adv Ther. 2025 Jan;42(1):427-441. doi: 10.1007/s12325-024-03032-3. Epub 2024 Nov 22.
10
Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.依库珠单抗预防治疗无抑制剂的 A 型血友病与因子 VIII 预防治疗的疗效：来自 HAVEN 3 试验的患者内比较的网络荟萃分析和亚组分析。
Curr Med Res Opin. 2019 Dec;35(12):2079-2087. doi: 10.1080/03007995.2019.1649378. Epub 2019 Aug 13.
本文引用的文献
1
Patient anti-FVIII drug antibodies bind preferentially to a subset of FVIII covalent states.患者的抗FVIII药物抗体优先结合FVIII共价状态的一个子集。
Blood Adv. 2025 Aug 12;9(15):3706-3715. doi: 10.1182/bloodadvances.2025016474.
2
Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada.重度血友病中依浓缩物进行抑制剂开发：来自欧洲和加拿大的1392例既往未治疗患者的报告。
Res Pract Thromb Haemost. 2023 Nov 20;7(8):102265. doi: 10.1016/j.rpth.2023.102265. eCollection 2023 Nov.
3
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.依库珠单抗预防伴抑制物的血友病 A。
N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10.
4
Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.法布里病的酶替代疗法：现有证据的系统评价
Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000.
Zotero 插件